News
According to UBS, the company’s next major driver is the SURPASS cardiovascular outcomes trial. The bank added that Eli Lilly ...
Eli Lilly and Company (NYSE:LLY) is one of the 13 best blue-chip stocks to buy, according to analysts. On June 30, RBC ...
3d
Zacks Investment Research on MSNHere is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending StockEli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...
Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...
Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...
Eli Lilly and Company (NYSE: LLY) today announced that the highest approved doses of Zepbound (tirzepatide)—12.5 mg and 15 mg—will soon be available in single-dose vials for $499 per month ...
Eli Lilly isn't a one-trick pony. The company's lineup of approved medicines features blockbusters like Verzenio, a cancer ...
Eli Lilly faces market headwinds, slowing growth, and rising competition. Discover why now might be the time for LLY ...
AbbVie announced it will acquire Capstan Therapeutics, a startup developing CAR-T therapies for autoimmune conditions, ...
After blueprinting an injectables facility in North Carolina in 2020, it didn’t take long for Eli Lilly to draw up designs ...
New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and ...
Eli Lilly and Company (NYSE:LLY) is among the Goldman Sachs Stock Portfolio: 10 Large-Cap Stocks To Buy. On June 25, the company announced that the FDA had approved a label update for Amyvid to ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results